C4 Ther­a­peu­tics cuts staff, re­struc­tures to fo­cus on lead pro­tein degra­da­tion pro­grams, dis­cov­ery pacts

With Phase I da­ta on its top de­grad­er can­di­dates in sight, C4 Ther­a­peu­tics is let­ting go of 45 staffers — or 30% of the com­pa­ny — in a bid to cut costs, it dis­closed Tues­day.

Like most of the biotechs that have down­sized in re­cent months, C4 said it’s con­cen­trat­ing re­sources on pro­grams with the high­est po­ten­tial for val­ue cre­ation and pa­tient im­pact. That means push­ing for­ward three clin­i­cal-stage can­di­dates — two in-house and one via a part­ner­ship with Chi­na’s Bet­ta Phar­ma­ceu­ti­cals — as well as a “stream­lined” in­ter­nal re­search pro­gram and dis­cov­ery col­lab­o­ra­tions with Roche, Bio­gen and Mer­ck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER